FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: MPV Exploration Inc. (the “Issuer”).

Trading Symbol: MPV

Number of Outstanding Listed Securities: 18,105,514

Date: Sept 4th, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

MPV is actively continuing to evaluate strategic opportunities, aiming to advance its projects and protect shareholder value. In furtherance of these initiatives, MPV engaged in various matters over the previous month in furtherance of its proposed amalgamation with Entheon (the “Amalgamation”) as further detailed in item 2 below.

In addition, a wholly-owned subsidiary of MPV (“Subco”) closed a private placement transaction (the “Private Placement”) in two tranches on August 28 and September 3, 2020, pursuant to which it issued an aggregate of 4,117,886 subscription receipts (“Subscription Receipts”) at a price of $0.375 per Subscription Receipt to raise aggregate gross proceeds of $1,544,207.25. Each Subscription Receipt will be deemed to be exchanged upon satisfaction of specified release conditions (“Release Conditions”) in connection with the Amalgamation, without payment of any additional consideration, for one unit of Subco (each a “Unit”). Each Unit will be comprised of one Class A non-voting common share in the capital of Subco (each, a “Subco Class A Share”) and one-half of one share purchase warrant of Subco (each whole warrant, a “Subco Warrant”), which entitles the holder thereof to purchase a Subco Class A Share at a price of $0.60 for a period of two years from the date the Subscription Receipts are converted into Units. In connection with the Amalgamation, each Subco Class A Share shall be exchanged for one common share of MPV (following a 1:3 consolidation) and each Subco Warrant shall be exchanged for one equivalent share purchase warrant of MPV based on the same exchange ratio. Following the Amalgamation, the net proceeds from the Private Placement are expected to be used to carry out preclinical and human proof of concept studies determining safety, tolerability and dose finding specific to DMT in the treatment of addictive disorders and for general working capital purposes. Please refer to item 14 below for further details.

1. Provide a general overview and discussion of the activities of management.

On June 30, the Company entered into a binding agreement with Entheon Biomedical Corp (“Entheon”) pursuant to which it will amalgamate with Entheon. This transaction will constitute a fundamental change for the company. Details of this transaction can be found in the Company’s press release dated July 2nd.

The Company also completed the Private Placement as noted in item 1 above.

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law. n/a
2. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned. n/a
3. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

n/a

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

n/a

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship. n/a
2. Describe the acquisition of new customers or loss of customers. n/a
3. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks. n/a
4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs. n/a
5. Report on any labour disputes and resolutions of those disputes if applicable. n/a
6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings. n/a
7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness. n/a
8. Provide details of any securities issued and options or warrants granted.

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds** |
| Subscription Receipts (of Subco) | 3,577,884 | August 28, 2020 | $1,341,706.50(1) |
| Subscription Receipts (of Subco) | 540,002 | September 3, 2020 | $202,500.75(1) |
|  |  |  |  |

1. *(1)*  Following the Amalgamation, the net proceeds from the Private Placement are expected to be used to carry out preclinical and human proof of concept studies determining safety, tolerability and dose finding specific to DMT in the treatment of addictive disorders and for general working capital purposes.Provide details of any loans to or by Related Persons. n/a
2. Provide details of any changes in directors, officers or committee members. n/a
3. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends. n/a

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 4th, 2020 .

 Nathalie Laurin
Name of Director or Senior Officer

 *Nathalie Laurin*
Signature

CFO
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerMPV Exploration Inc. | For Month EndAugust 2020 | Date of ReportYY/MM/D20/09/04 |
| Issuer Address1080 Beaver Hall, Suite 1606 |
| City/Province/Postal CodeMontreal, Quebec H2Z 1S8 | Issuer Fax No. | Issuer Telephone No.(514) 667-7171 |
| Contact NameNathalie Laurin | Contact PositionCFO | Contact Telephone No.(514) 667-7171 |
| Contact Email Addressnlaurin@mpvexploration.com | Web Site Address[www.mpvexploration.com](http://www.mpvexploration.com) |